Modern Wealth Management LLC Decreases Position in Zoetis Inc. $ZTS

Modern Wealth Management LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 45.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,282 shares of the company’s stock after selling 6,137 shares during the period. Modern Wealth Management LLC’s holdings in Zoetis were worth $1,065,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. CIBC Asset Management Inc boosted its stake in shares of Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after purchasing an additional 10,434 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its position in Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after purchasing an additional 18,040 shares during the period. Ninety One UK Ltd raised its position in Zoetis by 19.6% in the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after purchasing an additional 183,686 shares during the period. Quilter Plc lifted its stake in Zoetis by 10.2% in the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after purchasing an additional 40,615 shares during the last quarter. Finally, Swedbank AB lifted its stake in Zoetis by 60.4% in the third quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after purchasing an additional 917,598 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ZTS. KeyCorp assumed coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating on the stock. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Piper Sandler restated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. Finally, Barclays began coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Price Performance

Zoetis stock opened at $121.54 on Monday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock has a market cap of $51.31 billion, a price-to-earnings ratio of 20.19, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The firm has a 50-day moving average of $126.06 and a two-hundred day moving average of $132.88. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period last year, the company posted $1.40 earnings per share. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.